|
Sign In to gain access to subscriptions and/or personal tools.
|
This version was published on December
1, 2007
Statistical Methods in Medical Research, Vol. 16, No. 6,
523-537 (2007)
DOI: 10.1177/0962280206071847
Optimal designs for clinical trials with second-order polynomial treatment effects
Bjorn Winkens
Department of Methodology and Statistics, University of Maastricht, Maastricht, The Netherlands, Bjorn.Winkens{at}stat.unimaas.nl
Hubert J. A. Schouten
Department of Methodology and Statistics, University of Maastricht, Maastricht, The Netherlands
Gerard J. P. van Breukelen
Department of Methodology and Statistics, University of Maastricht, Maastricht, The Netherlands
Martijn P. F. Berger
Department of Methodology and Statistics, University of Maastricht, Maastricht, The Netherlands
The effect of adding intermediate measures on the efficiency of treatment effect estimation is considered for a second-order polynomial treatment effect, equidistant time-points, different covariance structures and two optimality criteria, assuming either a fixed sample size or a fixed budget. The benefit of adding intermediate measures (at the expense of subjects) depends strongly on the assumed covariance structure and is hardly affected by the two used optimality criteria (Ds or c). For a fixed sample size, the increase in efficiency by adding intermediate measures is large for a compound symmetric structure and small for a first-order auto-regressive structure. For a first-order auto-regressive structure with measurement error, the results depend on the covariance parameter values. For a fixed budget and linear cost function, the design with only three measures per subject is often highly efficient. If the structure resembles compound symmetry and the cost per subject is eight or more times larger than the cost per repeated measure, however, more than three measures are required to obtain highly efficient treatment effect estimators. If the covariance structure is unknown, the optimal design based on a first-order auto-regressive structure with measurement error is preferable in terms of robustness against misspecification of the covariance structure. Given a design with three repeated measures and a second-order polynomial treatment effect, equidistant time-points are either optimal (Ds- ) or highly efficient (c-optimality criterion). The results are illustrated by a practical example.
References
- Overall JE, Doyle SR Estimating sample sizes for repeated measurement designs. Controlled Clinical Trials 1994; 15: 100—23.[ISI][Medline]
[Order article via Infotrieve]
- Raudenbush SW, Liu X-F. Effects of study duration, frequency of observation, and sample size on power in studies of group differences in polynomial change. Psychological Methods 2001; 6: 387—401.[ISI][Medline]
[Order article via Infotrieve]
- Bloch DA Sample size requirements and the cost of a randomized clinical trial with repeated measurements. Statistics in Medicine 1986; 5: 663—67.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Lui K-J., Cumberland WG Sample size requirement for repeated measurements in continuous data. Statistics in Medicine 1992; 11: 633—41.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Atkinson AC, Donev AN Optimum experimental designs. Clarendon Press, 2002.
- Matthews Jns, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. British Medical Journal 1990; 300: 230—35.[ISI][Medline]
[Order article via Infotrieve]
- Pham B., Cranney A., Boers M., Verhoeven AC, Wells G., Tugwell P. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. Journal of Rheumatology 1999; 26: 712—16.[ISI][Medline]
[Order article via Infotrieve]
- Schiff M. A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies. Clinical Therapeutics 2003; 25: 993—1001.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Wong WK A unified approach to the construction of minimax designs. Biometrika 1992; 79: 611—19.[Abstract/Free Full Text]
- Agteresch HJ, Rietveld T., Kerkhofs Lgm, Van den Berg Jwo, Wilson Jhp, Dagnelie PC Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. Journal of Clinical Oncology 2002; 20: 371—78.[Abstract/Free Full Text]
- Diggle PJ, Liang K-Y., Zeger SL Analysis of longitudinal data. Oxford University Press, 1996.
- Moerbeek M., van Breukelen Gjp, Berger Mpf. Design issues for experiments in multilevel populations. Journal of Educational and Behavioral Statistics 2000; 25: 271—84.[Abstract/Free Full Text]
- Ouwens Jnm, Tan Fes, Berger Mpf. Maximin D-optimal designs for longitudinal mixed effects models. Biometrika 2002; 58: 735—41.
- Berger Mpf, Tan Fes. Robust designs for linear mixed effects models. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2004; 53: 569—81.[CrossRef][ISI]
- Bischoff W. Determinant formulas with applications to designing when the observations are correlated. Annals of the Institute of Statistical Mathematics 1995; 47: 385—99.
- Huang M-NL, Chang F-C., Wong WK D-optimal designs for polynomial regression without an intercept. Statistica Sinica 1995; 5: 441—58.[ISI]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
|
